Neuroprotective evaluation of zonisamide in patients with Parkinson's disease, using dopamine transporter scan (DAT scan)

Neuroprotective evaluation of zonisamide in patients with Parkinson's disease, using dopamine transporter scan (DAT scan) - Evaluation of zonisamide effects by DAT scan in patients with Parkinson's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022342

Enrollment

Registered

2016-06-01

Start date

2016-05-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Yale stage II and III in patients with Parkinson' disease

Exclusion criteria

Exclusion criteria: The present study was excluded the following 3 items. 1. Yale stage IV and V in patients with Parkinson' disease. 2. Patients with severe degree of dementia. 3. Patients interrupted zonisamide during the study. 4. Patients with iodine allergy.

Design outcomes

Primary

Measure	Time frame
The specific binding ratio (SBR) on DAT scan at the first (baseline) and second [the mean (SD) of 1.2 (0.2) years later]	—

Secondary

Measure	Time frame
UPDRS part II, part III and part IV at the first (baseline) and second [the mean (SD) of 1.2 (0.2) years later]	—

Countries

Japan

Contacts

Public ContactKen Ikeda

Toho University Omori Medical Center Department of Neurology

keni@med.toho-u.ac.jp03-3762-4151

Outcome results